Dan founded OBR in June 2011 out of frustration with the lack of academic/industry ties in the life sciences. Since then he's led OBR's expansion from Oxford across the UK, and to America, Singapore and Hong Kong – and now to over 20,000 members, and partnerships with the world's leading pharmaceutical companies. He also founded Marblar, a VC-backed product development company based in London that turns science into products. Partners include NASA, Penn, and Northwestern University. Originally from Miami, Dan is a dual-PhD student at Oxford and The Scripps Research Research Institute in California.
Sybil joined OBR as VP Business Development after submitting her thesis on a protein regulator of miRNA-mediated gene silencing as a PhD student jointly affiliated to the University of Nottingham and Barts Cancer Institute, Queen Mary, University of London. She obtained her BSc (Hons) in Biochemistry and Economics at the University of Hong Kong. In her free time, Sybil volunteers in North & East London to encourage hard-to-reach students to expand their horizons through studying science, complementing OBR's mission to facilitate young innovators to pursue their own ideas.
Tariq takes care of the OBR web internals and is an ardent code & systems enthusiast with an extensive full stack skill set. Coding for the past 16 years, he has built and shipped for desktop, enterprise and the web. Tariq's current interests include NodeJS, cluster networks and automated code refactoring. Aside from programming, he is passionate about design, photography and architecture; which he indulged in while being a part of the team that designed the Champalimaud Centre for the Unknown in Lisbon and the Aga Khan foundations’ Ismaili Centre in Toronto.
John is a JD student at Stanford Law School ('16) and has managed the OneStart biotech business plan competition since the inaugural competition in 2013, while studying a Masters in Neuroscience at Oxford. He completed his undergraduate degree at McGill University, studying Neuroscience and Philosophy. He hopes to work with emerging companies, particularly representing life science startups.